See more : LOTTE REIT Co., Ltd. (330590.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Neo-Concept International Group Holdings Limited (NCI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Neo-Concept International Group Holdings Limited, a leading company in the industry within the sector.
You may be interested
- Shanta Gold Limited (SAAGF) Income Statement Analysis – Financial Results
- Sydinvest Tyskland KL (SYITYSKADKK.CO) Income Statement Analysis – Financial Results
- Micropole S.A. (ALMIC.PA) Income Statement Analysis – Financial Results
- Wuxi Boton Technology Co., Ltd. (300031.SZ) Income Statement Analysis – Financial Results
- Dadi International Group Limited (8130.HK) Income Statement Analysis – Financial Results
Neo-Concept International Group Holdings Limited (NCI)
Website: https://www.neo-ig.com
About Neo-Concept International Group Holdings Limited
Neo-Concept International Group Holdings Limited provides one-stop apparel solution in Hong Kong. The company offers a suite of services in the apparel supply chain, including market trend analysis, product design and development, raw material sourcing, production and quality control, and logistics management. It sells knitwear/apparel products under the les 100 ciels brand. The company serves brand owners, apparel sourcing agents, and online fashion retailers primarily located in North America, the United Kingdom, and Europe. Neo-Concept International Group Holdings Limited was incorporated in 2021 and is based in Kwun Tong, Hong Kong. Neo-Concept International Group Holdings Limited operates as a subsidiary of Neo-concept (BVI) Limited.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 174.20M | 347.45M | 240.54M | 182.58M |
| Cost of Revenue | 139.15M | 305.62M | 217.94M | 170.93M |
| Gross Profit | 35.05M | 41.83M | 22.59M | 11.65M |
| Gross Profit Ratio | 20.12% | 12.04% | 9.39% | 6.38% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 18.23M | 20.12M | 14.70M | 12.83M |
| Selling & Marketing | 3.13M | 2.63M | 3.13M | 1.80M |
| SG&A | 21.36M | 22.75M | 17.83M | 14.63M |
| Other Expenses | 4.64M | 2.59M | 2.90M | 2.22M |
| Operating Expenses | 26.00M | 22.90M | 15.81M | 13.86M |
| Cost & Expenses | 165.16M | 328.52M | 233.75M | 184.79M |
| Interest Income | 92.95K | 1.00 | 1.00 | 0.00 |
| Interest Expense | 5.76M | 6.13M | 2.49M | 2.87M |
| Depreciation & Amortization | 3.41M | 18.96K | 37.04K | 319.74K |
| EBITDA | 14.90M | 21.67M | 1.28M | -4.94K |
| EBITDA Ratio | 8.56% | 6.24% | 4.15% | 0.19% |
| Operating Income | 9.05M | 18.94M | 4.47M | -3.65M |
| Operating Income Ratio | 5.19% | 5.45% | 1.86% | -2.00% |
| Total Other Income/Expenses | -3.31M | -3.55M | 2.72M | 455.44K |
| Income Before Tax | 5.74M | 15.38M | 7.19M | -3.19M |
| Income Before Tax Ratio | 3.29% | 4.43% | 2.99% | -1.75% |
| Income Tax Expense | 1.33M | 2.98M | 1.74M | 133.48K |
| Net Income | 4.41M | 12.40M | 5.45M | -3.33M |
| Net Income Ratio | 2.53% | 3.57% | 2.27% | -1.82% |
| EPS | 0.22 | 0.62 | 0.27 | -0.22 |
| EPS Diluted | 0.22 | 0.62 | 0.27 | -0.22 |
| Weighted Avg Shares Out | 20.00M | 20.00M | 20.00M | 15.00M |
| Weighted Avg Shares Out (Dil) | 20.00M | 20.00M | 20.00M | 15.00M |
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
Aptose's AML drug tuspetinib selected for NCI's prestigious clinical research program for ability to target broad spectrum of AML and MDS populations
Rakovina Therapeutics to Present Research Highlighting Small-Molecule Bifunctional Inhibitors of PARP1/2 and HDAC Enzymes at the 36th EORTC-NCI-AACR Symposium in Barcelona Spain
VANCOUVER, British Columbia, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response targeting technologies, is pleased to announce the presentation...
Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
CAPTN-3 demonstrates s ustained tumor regression in a triple negative breast cancer in-vivo model ; A dose dependent ac tivity and a synergistic effect of the engage r arm s also seen in non-small cell lung cancer patient-derived explants
IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024
~33% ORR by RECIST 1.1: 1 CR + 8 PRs out of 27 evaluable heavily pre-treated (median 2-3 prior lines, ranging from 1-7) MTAP-deletion UC and NSCLC patients 9 of 9 responses have confirmed by RECIST 1.1 (5 confirmed responses...
Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium
– Interim data from ongoing trial of PRT3789 showed additional clinical activity at higher doses in patients with non-small cell lung cancer (NSCLC)
Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
NEW CLINICAL DATA FROM ONGOING, PHASE 2 STUDY OF ORAL FADRACICLIB AT THE 2024 ENA SYMPOSIUM. Patients preselected for CDKN2A and/or CDKN2B abnormalities
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors
– Preclinical data demonstrate that inhibiting the p300 KAT domain reactivates p53 in HPV-driven tumors resulting in anti-tumor activity – – Preclinical data demonstrate that inhibiting the p300 KAT domain reactivates p53 in HPV-driven tumors resulting in anti-tumor activity –
Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors
– New preclinical data to be presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics – – New preclinical data to be presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics –
Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium
WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that new preclinical data from its innovative TPD...
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
DOYLESTOWN, Pa., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that four abstracts have been accepted for poster presentation at the...
Source: https://incomestatements.info
Category: Stock Reports